financetom
Business
financetom
/
Business
/
Intuit Reportedly Wins Appeals Court Ruling Over TurboTax Advertising Claims
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intuit Reportedly Wins Appeals Court Ruling Over TurboTax Advertising Claims
Mar 23, 2026 1:40 AM

04:12 AM EDT, 03/23/2026 (MT Newswires) -- Intuit (INTU) won a US appeals court ruling Friday that will allow it to continue advertising its TurboTax income tax preparation software as free even while many customers do not qualify for the option, news outlets reported Friday.

The Federal Trade Commission barred TurboTax from being promoted as free in 2024, a decision Intuit challenged in court, Reuters reported.

The appeals court ruled unanimously that an FTC administrative judge was not allowed to make such a decision on deceptive advertising and that the case should have been pursued in federal court, Reuters reported.

Intuit didn't immediately respond to MT Newswires' request for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Jun 2, 2025
03:46 AM EDT, 06/02/2025 (MT Newswires) -- Sanofi ( SNY ) has agreed to acquire Blueprint Medicines ( BPMC ) in a deal worth up to $9.5 billion, the companies said Monday. Under the deal, Sanofi ( SNY ) will launch a tender offer to acquire all outstanding shares of Blueprint for $129 each in cash, plus a contingent value...
AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial
AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial
Jun 2, 2025
04:08 AM EDT, 06/02/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer. The company said its combination therapy reduced the risk of disease progression or death by 56%...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint
Jun 2, 2025
04:02 AM EDT, 06/02/2025 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) and Takeda (TAK) said Sunday their investigational drug rusfertide as a potential treatment for patients with polycythemia vera met primary and key secondary endpoints in a randomized, placebo-controlled phase 3 study. The companies, which are co-developing the drug, said 76.9% of patients in the 156-week, 293-patient study receiving...
Copyright 2023-2026 - www.financetom.com All Rights Reserved